{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T19:15:03Z","timestamp":1782414903658,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.xphs.2024.01.019","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T07:24:56Z","timestamp":1707204296000},"page":"1682-1688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["How to Evaluate If Microorganisms Isolated From Sterile Drug Production Environments Monitoring Are Undesirable"],"prefix":"10.1016","volume":"113","author":[{"given":"Stefano","family":"Ceccanti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Vecchiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Leonangeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susi","family":"Burgalassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3890-8546","authenticated-orcid":false,"given":"Ileana","family":"Federigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalaura","family":"Carducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Verani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2024.01.019_bib0001","unstructured":"European Union. Commission Directive 2003\/94\/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use. Available at: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=celex%3A32003L0094 (last accessed on 22 November 2023)."},{"key":"10.1016\/j.xphs.2024.01.019_bib0002","series-title":"Eudralex. The Rules Governing Medicinal Products in the European Union,Volume 4: Good Manufacturing Practice for Medicinal Products for Human and Veterinary use, Annex 1- Manufacture of sterile medicinal products","year":"2022"},{"key":"10.1016\/j.xphs.2024.01.019_bib0003","unstructured":"Sutton S. Understand your facility's microflora. In: Madsen RE, Moldenhauer J, eds. Contamination control in healthcare product manufacturing, Vol. 1. PDA\/DHI: Bethesda, MD, 2014; pp 17-19"},{"issue":"6","key":"10.1016\/j.xphs.2024.01.019_bib0004","first-page":"36","article-title":"What is an objectionable MO?","volume":"15","author":"Sutton","year":"2012","journal-title":"Am. Pharm. Rev"},{"key":"10.1016\/j.xphs.2024.01.019_bib0005","series-title":"Technical Report no 13. Fundamentals of Environmental Monitoring Program","year":"2022"},{"key":"10.1016\/j.xphs.2024.01.019_bib0006","series-title":"Guidance for industry. Sterile drug products produced by aseptic processing - current good manufacturing practice","year":"2004"},{"key":"10.1016\/j.xphs.2024.01.019_bib0007","series-title":"Medical Devices, and Cosmetics","article-title":"Technical Report No 67. Exclusion of Objectionable MOs from Nonsterile Pharmaceuticals","year":"2014"},{"key":"10.1016\/j.xphs.2024.01.019_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105984","article-title":"Objectionable microorganisms in pharmaceutical production: Validation of a decision tree","volume":"166","author":"Burgalassi","year":"2021","journal-title":"Eur. J. Pharm. Sci"},{"key":"10.1016\/j.xphs.2024.01.019_bib0009","unstructured":"Haberer K. Identification of environmental isolate. In: Moldenhauer J eds. Environmental monitoring, a comprehensive handbook, Vol. 2, PDA\/DHI: Bethesda, MD, 2008; pp 111-136"},{"key":"10.1016\/j.xphs.2024.01.019_bib0010","series-title":"ICH guideline Q10 on pharmaceutical quality system. Committee for Human Medicinal Products","year":"2015"},{"key":"10.1016\/j.xphs.2024.01.019_bib0011","series-title":"Code of Federal Regulations. Title 21 - Food and Drugs. Part 820 - Quality System Regulation. Section 820.100 - Corrective and preventive action","year":"2023"},{"key":"10.1016\/j.xphs.2024.01.019_bib0012","series-title":"Boca Ration (FL)","first-page":"17","article-title":"Guide to microbiological control in pharmaceuticals and medical devices","author":"Denyer","year":"2007"},{"issue":"5","key":"10.1016\/j.xphs.2024.01.019_bib0013","doi-asserted-by":"crossref","first-page":"e10598","DOI":"10.1371\/journal.pone.0010598","article-title":"The human nasal microbiota and Staphylococcus aureus carriage","volume":"5","author":"Frank","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.xphs.2024.01.019_bib0014","unstructured":"Hubka GG. Microbial control: mold. In: Madsen RE, Moldenhauer J, eds. Contamination control in healthcare product manufacturing, Vol. 1. PDA\/DHI: Bethesda, MD, 2013; pp 257-275."},{"key":"10.1016\/j.xphs.2024.01.019_bib0015","series-title":"General chapter <1116>Microbiological control and monitoring of aseptic processing environments","year":"2021"},{"issue":"3","key":"10.1016\/j.xphs.2024.01.019_bib0016","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5731\/pdajpst.2014.005165","article-title":"Cleaning and Disinfection of Bacillus cereus Biofilm","volume":"70","author":"Deal","year":"2016","journal-title":"PDA J. Pharm. Sci. Technol"},{"key":"10.1016\/j.xphs.2024.01.019_bib0017","series-title":"Bergey's Manual of Systematic Bacteriology","first-page":"661","article-title":"Volume Two: The Proteobacteria. Part B: The Gammaproteobacteria","author":"Brenner","year":"2005"},{"issue":"1","key":"10.1016\/j.xphs.2024.01.019_bib0018","first-page":"42","article-title":"Review of Reported Recalls Involving Microbiological Control 2004-2011 with Emphasis on FDA Considerations of Objectionable Organisms","volume":"15","author":"Sutton","year":"2012","journal-title":"Am. Pharm. Rev"},{"key":"10.1016\/j.xphs.2024.01.019_bib0019","unstructured":"Moldenhauer J. The problem of Burkholderia cepacia. In: Madsen RE, Moldenhauer J, eds. Contamination control in healthcare product manufacturing, Vol. 3. PDA\/DHI: Bethesda, MD, 2014; pp 261-284"},{"key":"10.1016\/j.xphs.2024.01.019_bib0020","series-title":"Guidelines for the Prevention and Control of Carbapenem-Resistant, Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in Health Care Facilities","year":"2017"},{"key":"10.1016\/j.xphs.2024.01.019_bib0021","doi-asserted-by":"crossref","unstructured":"Brenner DJ, Krieg NR & Staley JT. Volume Two: The Proteobacteria. Part C: The Alpha-, Beta-, Delta-, and Epsilonproteobacteria. In: G.M. Garrity (ed.), Bergey's Manual of Systematic Bacteriology, Second Edition. Springer: Berlin, 2005; pp. 777-798.","DOI":"10.1007\/0-387-29298-5"},{"key":"10.1016\/j.xphs.2024.01.019_bib0022","series-title":"Bergey's Manual of Systematic Bacteriology","first-page":"465","article-title":"Volume Three: The Firmicutes","author":"Brenner","year":"2005"},{"issue":"7","key":"10.1016\/j.xphs.2024.01.019_bib0023","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1099\/mic.0.000086","article-title":"Non-pathogenic Neisseria: members of an abundant, multi-habitat, diverse genus","volume":"161","author":"Liu","year":"2015","journal-title":"Microbiology"},{"key":"10.1016\/j.xphs.2024.01.019_bib0024","first-page":"10","article-title":"Yet Not Infrequent","volume":"9","author":"Humbert","year":"2019"},{"issue":"2","key":"10.1016\/j.xphs.2024.01.019_bib0025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2340\/0001555557177180","article-title":"Survival of Neisseria gonorrhoeae on surfaces","volume":"57","author":"Elmros","year":"1977","journal-title":"Acta Derm. Venereol"},{"key":"10.1016\/j.xphs.2024.01.019_bib0026","first-page":"89","article-title":"The Human Microbiome and the implications for cleanroom control","volume":"23","author":"Sandle","year":"2018","journal-title":"Eu. J. Parenter. Pharm. Sci"},{"key":"10.1016\/j.xphs.2024.01.019_bib0027","article-title":"Tracking and tracing to the root cause: case studies in microbial contamination","author":"Sandle","year":"2022","journal-title":"Eu. Pharm. Rev"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924000406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924000406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T05:02:32Z","timestamp":1739422952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354924000406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0022354924000406"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2024.01.019","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to Evaluate If Microorganisms Isolated From Sterile Drug Production Environments Monitoring Are Undesirable","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2024.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}